Novo Nordisk A/S (NVO)
| Market Cap | 227.37B |
| Revenue (ttm) | 49.11B |
| Net Income (ttm) | 17.49B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.93 |
| PE Ratio | 12.96 |
| Forward PE | 12.94 |
| Dividend | $1.18 (2.32%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 19,371,177 |
| Open | 50.28 |
| Previous Close | 49.78 |
| Day's Range | 50.24 - 51.24 |
| 52-Week Range | 45.05 - 139.74 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 112.00 (+120.04%) |
| Earnings Date | Aug 6, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $112.0, which is an increase of 120.04% from the latest price.
News
A Cure For Novo Nordisk
NVO has sector headwinds and product growth concerns. These problems don't have an easy solution and the market has administered its own cure - a 70% drop. The bad news should be mostly priced in. $47...
Novo Nordisk: The Falling Knife That Keeps Giving
Novo Nordisk remains a buy despite share price weakness, as strong earnings and robust market share in diabetes and obesity care drive growth. The company's pipeline is rich, with late-stage R&D in ob...
Why is Novo Nordisk excluding Hims & Hers in its lawsuits over Wegovy copies?
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers. The high-profil...
Novo Nordisk: Watching Value Investors Buy The Dip Hurts My Eyes
I was right with my Strong Sell rating for Novo Nordisk A/S and the main pillar of my bear case: market share erosion in weight loss treatment. FY 2025 guidance cuts—sales 8–14% CER and operating prof...
Novo Nordisk: Enough Is Enough
Novo Nordisk A/S's Q2 earnings disappointed as management issued a cautious growth outlook, but I believe the market overreacted to these headwinds. Despite competition and knock-off products, Novo No...
Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities
I invest for long-term total return, prioritizing dividend growth and quality companies trading at bargain valuations, especially during industry downturns. Despite current headwinds like tariffs and ...
As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims?
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers.
Why I Tripled My Novo Nordisk Position
Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below historical averages. Despite lowered 2025 guidance and slower growth, core products...
Novo Nordisk: This Won't Last
Novo Nordisk is still the GLP-1 king, with over 65% market share and blockbuster drugs like Ozempic and Wegovy continuing to drive global growth. The recent stock correction presents a rare long-term ...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...
Novo Nordisk extends rebound on Eli Lilly trial results: are investors reversing positions?
Novo Nordisk shares rose over 5% in morning trade on Friday, ranking among the top gainers on the STOXX index, after investors reacted to trial results from Eli Lilly's oral obesity drug candidate, or...
The rise, fall and rise again of Novo Nordisk shares
CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares.
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...
Final Trade: AAPL, NOVO, RL
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit – NVO
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Drugmakers racing to launch the first weight-loss pill
Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's Wegovy.
VIEW Lilly's obesity pill lags Novo's Wegovy injection in key trial
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's in...
Novo Nordisk: The Market Has Lost Its Mind
Novo Nordisk's shares have dropped significantly despite appealing Q2 results, creating an attractive entry point for long-term investors. The company continues to deliver double-digit revenue and pro...
Novo Nordisk shares jump as Eli Lilly's weight-loss pill data disappoints
Shares in Novo Nordisk rose 13.6% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell short of expectations, boosting investor confidence in the Danish drugmaker's market-...
Novo Nordisk: More Pain On The Horizon
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook, signaling challenges ahead. Competition from Eli Lilly is intensifying, forcing Novo to increase marke...
Novo Nordisk A/S (NVO) Q2 2025 Earnings Call Transcript
Novo Nordisk A/S (NVO) Q2 2025 Earnings Conference Call August 6, 2025 7:00 AM ET Company Participants David S. Moore - Executive VP of US Operations & Member of Management Board Jacob Martin Wiborg R...
Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues
Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded versions of the drug.
Wegovy maker Novo Nordisk's sales hike in second quarter
Wegovy maker Novo Nordisk's sales hike in second quarter
Wegovy maker Novo Nordisk sales rise 18% in second quarter
Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a major profit warning and new CEO announcement last week wiped some $95 billion ...
Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025
Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025